Results 71 to 80 of about 107,851 (315)

Vancomycin dosing design method considering risk factors for nephrotoxicity

Journal of Pharmaceutical Health Care and Sciences
Background Vancomycin (VCM) induces nephrotoxicity in a dose-dependent manner, and patients with risk factors for nephrotoxicity have been reported to develop nephrotoxicity even within the effective concentration range.
Yoshihiko Matsuki, Yutaro Kozima, Megumi Yanagi, Ken-ichi Sako, Tamaki Watanabe, Nobuhiro Yasuno, Shigekazu Watanabe   +6 more
doaj   +1 more source

Predictive usefulness of urinary biomarkers for the identification of cyclosporine A-induced nephrotoxicity in a rat model.

PLoS ONE, 2014
The main side effect of cyclosporine A (CsA), a widely used immunosuppressive drug, is nephrotoxicity. Early detection of CsA-induced acute nephrotoxicity is essential for stop or minimize kidney injury, and timely detection of chronic nephrotoxicity is ...
Carla Patrícia Carlos, Nathália Martins Sonehara, Sonia Maria Oliani, Emmanuel A Burdmann   +3 more
doaj   +1 more source

Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. [PDF]

PLoS ONE, 2014
Nephrotoxicity remains a problem for patients who receive cisplatin chemotherapy. We retrospectively evaluated potential risk factors for cisplatin-induced nephrotoxicity as well as the potential impact of intravenous magnesium supplementation on such ...
Yasuhiro Kidera, Hisato Kawakami, Tsutomu Sakiyama, Kunio Okamoto, Kaoru Tanaka, Masayuki Takeda, Hiroyasu Kaneda, Shin-ichi Nishina, Junji Tsurutani, Kimiko Fujiwara, Morihiro Nomura, Yuzuru Yamazoe, Yasutaka Chiba, Shozo Nishida, Takao Tamura, Kazuhiko Nakagawa   +15 more
doaj   +1 more source

Contraindicated drug–drug interactions and associated adverse drug reactions in an observational cohort study of 4543 paediatric hospitalized patients

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background and Purpose Drug–drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequent use of unlicensed or off‐label medications, and dosing regimens often extrapolated from adult data.
Emilie Laval, Sylvain Goutelle, Inesse Boussaha, Xavier Dode, Yanis Mimouni, Kim An Nguyen, Behrouz Kassai   +6 more
wiley   +1 more source

Metabolomic investigation of cisplatin‐induced acute kidney injury in paediatric cancer patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Cisplatin causes acute kidney injury (AKI) in approximately 46% of paediatric cancer patients who receive it. Serum creatinine (SCr) is a poor biomarker of cisplatin nephrotoxicity, because there is a delay between cisplatin infusion and SCr elevation.
Yong Jin Lim, Amy Thachil, Kelly McMahon, Ross T. Tsuyuki, S. Rod Rassekh, Lesley G. Mitchell, Prasad Devarajan, Cherry Mammen, Bruce C. Carleton, Geoffrey D. E. Cuvelier, Victor A. Lewis, Colin J. D. Ross, Alexandra P. Zorzi, Sylvain Baruchel, Raveena Ramphal, Eric Bouffet, Mathieu Lemaire, Tom D. Blydt‐Hansen, Brad L. Urquhart, The Applying Biomarkers to Minimize Long‐Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Study Group, Tom Blydt‐Hansen, Bruce C. Carleton, Geoff D. E. Cuvelier, Sunil Desai, Prasad Devarajan, Conrad Fernandez, Adam Fleming, Paul Gibson, Caroline Laverdiere, Victor Lewis, Mary L. McBride, Bruno Michon, Shahrad Rod Rassekh, Colin J. D. Ross, Christine Sabapathy, Kirk R. Schultz, Michael Zappitelli, Alexandra Zorzi   +37 more
wiley   +1 more source

Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review

Frontiers in Pharmacology, 2018
Background: Nephrotoxicity is a notable adverse effect in cisplatin treated patients characterized by tubular injury and/or increased serum creatinine (SCr) with incidence varying from 20 to 70%.
Zulfan Zazuli, Zulfan Zazuli, Susanne Vijverberg, Elise Slob, Geoffrey Liu, Geoffrey Liu, Bruce Carleton, Bruce Carleton, Bruce Carleton, Joris Veltman, Paul Baas, Paul Baas, Rosalinde Masereeuw, Anke-Hilse Maitland-van der Zee   +13 more
doaj   +1 more source

Cyclosporine Nephrotoxicity [PDF]

Toxicologic Pathology, 1986
Cyclosporine (CSA) is a new immunosuppressant which has selectivity for the immune system and is without systemic side effects at therapeutic doses. In contrast to the cytotoxic class of immunosuppressants, no myelotoxic, teratogenic, mutagenic, or carcinogenic effects were observed.
B, Ryffel, M J, Mihatsch
openaire   +2 more sources

Supratherapeutic drug concentration triggers: A novel data‐driven approach to assess their value for medication safety surveillance in intensive care

British Journal of Clinical Pharmacology, EarlyView.
Aims Electronic triggers (e‐triggers) are used as screening signals to detect potential adverse drug events (ADEs) and offer an effective system level approach for medication safety surveillance. Their clinical utility is typically evaluated through time‐consuming manual chart review by experts, limiting implementation.
Anne Paulien Langermans, Izak A. R. Yasrebi‐de Kom, Dylan Wayne de Lange, Nicolette Fransisca de Keizer, Joanna E. Klopotowska, on behalf of the RESCUE Study group, C. S. C. Bouman, E. N. van Roon, P. F. Schutte, J. ten Cate, D. van Balen, S. Hendriks, C. Lau, W. J. Vermeijden, A. Beishuizen, J. B. Masselink, P. E. Spronk, H. J. M. van Kan, P. W. de Feiter, E. J. Wils, A. Wieringa, A. J. Valkenburg, W. M. van den Bergh, M. H. Renes, W. Bult, E. de Jonge, M. Hoeksema, E. J. Wesselink, I. M. Purmer, B. E. Bosma, S. H. W. van Bree, H. J. W. Lammers, R. J. Bosman, E. J. F. Franssen, A. Karakus, M. Sigtermans, E. M. Kuck, D. A. Dongelmans, M. J. H. Aries, E. V. Uijtendaal, M. C. Reuland   +40 more
wiley   +1 more source

Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study

BMC Pharmacology and Toxicology, 2019
Background Nephrotoxicity and ototoxicity are clinically significant dose-related adverse effects associated with second-line anti-tubercular injectables drugs (aminoglycosides and capreomycin) used during intensive phase of treatment of multi-drug ...
Workineh Shibeshi, Anandi N. Sheth, Addisu Admasu, Alemseged Beyene Berha, Zenebe Negash, Getnet Yimer   +5 more
doaj   +1 more source

Tobramycin pharmacokinetic and pharmacodynamic targets in people with cystic fibrosis

British Journal of Clinical Pharmacology, EarlyView.
Intravenous tobramycin is a first‐line treatment for Pseudomonas aeruginosa infection in people with cystic fibrosis (CF). Tobramycin exhibits concentration‐dependent activity; however, excess drug exposure can lead to nephrotoxicity and ototoxicity. While dosing typically targets serum peak (Cmax) and trough (Cmin) concentrations, the area under the ...
Kiera H. Harwood, Sarah Bannister, Stephen Duffull, April Martinez, Sarath Ranganathan, Shivanthan Shanthikumar, Amanda Gwee   +6 more
wiley   +1 more source